

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**207500Orig1s000 / 207501Orig1s000**

***Trade Name:*** Cresemba Capsules, 186 mg. &  
Cresemba Powder for Injection, 372 mg

***Generic Name:*** Isavuconazonium Sulfate

***Sponsor:*** Astellas Pharma US Inc.

***Approval Date:*** March 6, 2015

***Indications:*** For the treatment of invasive aspergillosis and  
invasive mucormycosis.

For Injection for the treatment of invasive  
aspergillosis and invasive mucormycosis

# **CENTER FOR DRUG EVALUATION AND RESEARCH**

**207500Orig1s000 / 207501Orig1s000**

## **CONTENTS**

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                         |          |
|---------------------------------------------------------|----------|
| <b>Approval Letter</b>                                  | <b>X</b> |
| <b>Other Action Letters</b>                             |          |
| <b>Labeling</b>                                         | <b>X</b> |
| <b>REMS</b>                                             |          |
| <b>Summary Review</b>                                   | <b>X</b> |
| <b>Officer/Employee List</b>                            | <b>X</b> |
| <b>Office Director Memo</b>                             | <b>X</b> |
| <b>Cross Discipline Team Leader Review</b>              | <b>X</b> |
| <b>Medical Review(s)</b>                                | <b>X</b> |
| <b>Chemistry Review(s)</b>                              | <b>X</b> |
| <b>Environmental Assessment</b>                         |          |
| <b>Pharmacology Review(s)</b>                           | <b>X</b> |
| <b>Statistical Review(s)</b>                            | <b>X</b> |
| <b>Microbiology / Virology Review(s)</b>                | <b>X</b> |
| <b>Clinical Pharmacology/Biopharmaceutics Review(s)</b> | <b>X</b> |
| <b>Other Reviews</b>                                    | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>    | <b>X</b> |
| <b>Proprietary Name Review(s)</b>                       | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>        | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**207500Orig1s000 / 207501Orig1s000**

**APPROVAL LETTER**



NDA 207500

**NDA APPROVAL**

Astellas Pharma US Inc.  
Attention: Robert M. Reed  
Senior Director, Regulatory Affairs  
1 Astellas Way  
Northbrook, IL 60062

Dear Mr. Reed:

Please refer to your New Drug Application (NDA) dated July 8, 2014, received July 8, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cresemba (isavuconazonium sulfate) Capsules, 186 mg.

We acknowledge receipt of your amendments dated July 29, August 13, and 25, September 16, 22, 26, and 30, October 8, and 14, November 14, 17, 18 (2), and 25, December 11, 12, and 18, 2014; and January 6, and 8, February 6, 9, 19, 20 (3), 23, and 27 (2), and March 3 (2), and 5, 2015.

This new drug application provides for the use of Cresemba (isavuconazonium sulfate) Capsules for the treatment of invasive aspergillosis and invasive mucormycosis.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission **“Final Printed Carton and Container Labels for approved NDA 207500.”** Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **MARKET PACKAGE**

Please submit one market package of the drug product when it is available to the following address:

Alison Rodgers  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 6247  
10903 New Hampshire Avenue  
Silver Spring, Maryland  
*Use zip code **20903** if shipping via United States Postal Service (USPS).*  
*Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because the drug product for this indication has an orphan drug designation, you are exempt from this requirement.

### **POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a known serious risk of development of resistance to Cresemba (isavuconazonium sulfate) in microorganisms specific to invasive aspergillosis and invasive mucormycosis, or to assess signals of serious risk of malignancy.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

- 2872-1: Conduct a prospective study over a five-year period to determine if decreased susceptibility to Cresemba (isavuconazonium sulfate) is occurring in the target population of organisms that are in the approved Cresemba (isavuconazonium sulfate) label.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 09/2015 |
| Interim Report:            | 09/2016 |
| Interim Report:            | 09/2017 |
| Interim Report:            | 09/2018 |
| Interim Report:            | 09/2019 |
| Study Completion:          | 07/2020 |
| Final Report Submission:   | 10/2020 |

- 2872-2: Conduct a two year mouse carcinogenicity study.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 04/2016 |
| Study Completion:          | 03/2019 |
| Final Report Submission:   | 05/2019 |

- 2872-3: Conduct a two year rat carcinogenicity study.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 04/2016 |
| Study Completion:          | 03/2019 |
| Final Report Submission:   | 05/2019 |

Submit the protocols to your IND 119307, with a cross-reference letter to this NDA. Submit all final reports to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **“Required Postmarketing Protocol Under 505(o)”, “Required Postmarketing Final Report Under 505(o)”, “Required Postmarketing Correspondence Under 505(o)”**.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

#### **POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitment:

- 2872-4: Establish a registry to collect and analyze clinical efficacy-related outcome data on patients treated with isavuconazonium sulfate who have invasive mucormycosis or infection with non-fumigatus aspergillus species.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 03/2016 |
| Interim Report:            | 03/2018 |
| Interim Report:            | 03/2019 |
| Interim Report:            | 03/2020 |
| Study Completion:          | 01/2022 |
| Final Report Submission:   | 01/2023 |

Submit clinical protocols to your IND 119307 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in

plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol,**” “**Postmarketing Commitment Final Report,**” or “**Postmarketing Commitment Correspondence.**”

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

### **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at

<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

## **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

## **PDUFA V APPLICANT INTERVIEW**

FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs under PDUFA V ('the Program'). The PDUFA V Commitment Letter states that these assessments will include interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a PDUFA V applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

*{See appended electronic signature page}*

John Farley, MD, MPH  
Deputy Director  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOHN J FARLEY  
03/06/2015



NDA 207501

**NDA APPROVAL**

Astellas Pharma US Inc.  
Attention: Robert M. Reed  
Senior Director, Regulatory Affairs  
1 Astellas Way  
Northbrook, IL 60062

Dear Mr. Reed:

Please refer to your New Drug Application (NDA) dated July 8, 2014, received July 8, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cresemba (isavuconazonium sulfate) Powder for Injection, 372 mg.

We acknowledge receipt of your amendments dated July 29, August 13, and 25, September 16, 22, 26, and 30, October 8, and 14, November 14, 17, 18 (2), and 25, December 11, 12, and 18, 2014; and January 6, and 8, February 6, 9, 19, 20 (3), 23, and 27 (2), and March 3 (2), and 5, 2015.

This new drug application provides for the use of Cresemba (isavuconazonium sulfate) Powder for Injection for the treatment of invasive aspergillosis and invasive mucormycosis.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission **“Final Printed Carton and Container Labels for approved NDA 207501.”** Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

## **MARKET PACKAGE**

Please submit one market package of the drug product when it is available to the following address:

Alison Rodgers  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 6247  
10903 New Hampshire Avenue  
Silver Spring, Maryland  
*Use zip code **20903** if shipping via United States Postal Service (USPS).*  
*Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because the drug product for this indication has an orphan drug designation, you are exempt from this requirement.

## **POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a known serious risk of development of resistance to Cresemba (isavuconazonium sulfate) in microorganisms specific to invasive aspergillosis and invasive mucormycosis, or to assess signals of serious risk of malignancy.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following:

- 2872-1: Conduct a prospective study over a five-year period to determine if decreased susceptibility to Cresemba (isavuconazonium sulfate) is occurring in the target population of organisms that are in the approved Cresemba (isavuconazonium sulfate) label.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 09/2015 |
| Interim Report:            | 09/2016 |
| Interim Report:            | 09/2017 |
| Interim Report:            | 09/2018 |
| Interim Report:            | 09/2019 |
| Study Completion:          | 07/2020 |
| Final Report Submission:   | 10/2020 |

- 2872-2: Conduct a two-year mouse carcinogenicity study.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 04/2016 |
| Study Completion:          | 03/2019 |
| Final Report Submission:   | 05/2019 |

- 2872-3: Conduct a two-year rat carcinogenicity study.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 04/2016 |
| Study Completion:          | 03/2019 |
| Final Report Submission:   | 05/2019 |

Submit the protocols to your IND 72593, with a cross-reference letter to this NDA. Submit all final reports to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **“Required Postmarketing Protocol Under 505(o)”, “Required Postmarketing Final Report Under 505(o)”, “Required Postmarketing Correspondence Under 505(o)”**.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

#### **POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitment:

- 2872-4: Establish a registry to collect and analyze clinical efficacy-related outcome data on patients treated with isavuconazonium sulfate who have invasive mucormycosis or infection with non-fumigatus aspergillus species.

The timetable you submitted on March 3, 2015, states that you will conduct this study according to the following schedule:

|                            |         |
|----------------------------|---------|
| Final Protocol Submission: | 03/2016 |
| Interim Report:            | 03/2018 |
| Interim Report:            | 03/2019 |
| Interim Report:            | 03/2020 |
| Study Completion:          | 01/2022 |
| Final Report Submission:   | 01/2023 |

Submit clinical protocols to your IND 72593 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each

study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

### **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at

<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

### **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from

improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

### **PDUFA V APPLICANT INTERVIEW**

FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs under PDUFA V ('the Program'). The PDUFA V Commitment Letter states that these assessments will include interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a PDUFA V applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

*{See appended electronic signature page}*

John Farley, MD, MPH  
Deputy Director  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JOHN J FARLEY  
03/06/2015